December 20, 2024 10:16 AM EST
News Briefing

Idor­sia’s Tryvio deal de­lay; Galectin’s liv­er drug dis­ap­points

Ayisha Sharma

News Reporter

Plus, news about Pyx­is, Epi­to­pea and Genevant:

Idor­sia’s deal for blood pres­sure drug hits snag: The Swiss com­pa­ny

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Sage sues Bio­gen days af­ter $469M buy­out of­fer

Sion­na and Odyssey end JPM week with IPO fil­ings

An­oth­er US biotech emerges with drug can­di­date from Chi­na-based Keymed

Ozem­pic makes list for next round of Medicare drug price ne­go­ti­a­tions

What Trump's CMS can and can't change with the sec­ond round of drug price ne­go­ti­a­tions

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times